

**Announcement No. 5/2009  
1 April 2009****British health care reform: Final update**

The UK Department of Health ("DH") has today announced its decisions on reform of Part IX of the Drug Tariff, following an extensive review process. The changes have implications for the reimbursement prices for stoma and continence appliances and the system of remuneration for related services provided by Dispensing Appliance Contractors ("DACs") in England.

DH has announced a uniform 2% reduction in reimbursement prices for Part IX of the Drug Tariff that covers urinary and urethral, incontinence and stoma appliances.

The DH has also announced additional reforms relating to remuneration for services which will replace the existing on-cost allowance with an arrangement that will create greater transparency between remuneration for services and reimbursement for items.

The changes to reimbursement prices and the system of remuneration for services will come into force on 1<sup>st</sup> April 2010 and therefore will not impact the financial expectations for 2008/09.

Coloplast estimate the impact of the changes to be an annual reduction in revenues and profitability (EBIT) of GBP 3-4m. A price increase mechanism for the reimbursement of items – frozen during the review - will be reintroduced 6 months after implementation of the price reduction, in October 2010.

This brings to a conclusion the entire Part IX review.

Further details are available in Department of Health documentation on the website [www.dh.gov.uk](http://www.dh.gov.uk).

Lene Skole  
CFO

## **For further information, please contact**

### **Investors and analysts**

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1665

Ian S.E. Christensen  
Head of Investor Relations  
Tel. +45 4911 1301/+45 3085 1301  
Email: dkisec@coloplast.com

### **Press and the media**

Elisabeth Geday  
Director of External Relations  
Tel. +45 4911 1922/+45 3085 1922  
Email: dkege@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

*Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.*